Publications by authors named "Christophe Queva"

Claim this Profile
R
Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy.
Federico Giovannoni, Craig A Strathdee, Camilo Faust Akl, Brian M Andersen, Zhaorong Li

Nat Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity.
Camilo Faust Akl, Brian M Andersen, Zhaorong Li, Federico Giovannoni, Martin Diebold

Nature· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seneca Valley virus replicons are packaged in and have the capacity to overcome the limitations of viral transgene expression.
Jeffrey D Bryant, Jennifer S Lee, Ana De Almeida, Judy Jacques, Ching-Hung Chang

Mol Ther Oncolytics· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer.
Edward M Kennedy, Agnieszka Denslow, Jacqueline Hewett, Lingxin Kong, Ana De Almeida

Nat Commun· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic HSV Vectors and Anti-Tumor Immunity.
Joseph C Glorioso, Justus B Cohen, William F Goins, Bonnie Hall, Joseph W Jackson

Curr Issues Mol Biol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity.
Brian B Haines, Agnieszka Denslow, Peter Grzesik, Jennifer S Lee, Terry Farkaly

Cancer Immunol Res· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability.
Edward M Kennedy, Terry Farkaly, Peter Grzesik, Jennifer Lee, Agnieszka Denslow

Mol Ther Oncolytics· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9.
Hans-Georg Wirsching, Sonali Arora, Huajia Zhang, Frank Szulzewsky, Patrick J Cimino

Neuro Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
Hans-Georg Wirsching, Huajia Zhang, Frank Szulzewsky, Sonali Arora, Paola Grandi

JCI Insight· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.
Daniel Primo, Lydia Scarfò, Aliki Xochelli, Mattias Mattsson, Pamela Ranghetti

Oncotarget· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Anella Yahiaoui, Sarah A Meadows, Rick A Sorensen, Zhi-Hua Cui, Kathleen S Keegan

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Qingshan Yang, Prexy Modi, Terry Newcomb, Christophe Quéva, Varsha Gandhi

Clin Cancer Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
Kathleen Keegan, Cong Li, Zhihong Li, Ji Ma, Mark Ragains

Mol Cancer Ther· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.
Zhihong Li, Xianghong Wang, John Eksterowicz, Michael W Gribble, Grace Q Alba, Christophe Queva

J Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptibodies: A flexible alternative format to antibodies.
Grant Shimamoto, Colin Gegg, Tom Boone, Christophe Quéva

MAbs· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Gadi Gazit Bornstein, Christophe Quéva, Mohammad Tabrizi, Anne van Abbema, Carlos Chavez

Invest New Drugs· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Sonya D Zabludoff, Chun Deng, Michael R Grondine, Adam M Sheehy, Susan Ashwell, Christophe Queva

Mol Cancer Ther· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of GABA agonists on body temperature regulation in GABA(B(1))-/- mice.
Christophe Quéva, Marianne Bremner-Danielsen, Anders Edlund, A Jonas Ekstrand, Susanne Elg

Br J Pharmacol· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis